Perrigo (PRGO) Misses Q4 EPS by 3c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Perrigo Co. (PRGO) PT Lowered to $48 at RBC Capital
February 28, 2019 6:48 AM ESTRBC Capital analyst Randall Stanicky lowered the price target on Perrigo Co. (NYSE: PRGO) to $48.00 (from $50.00) while maintaining a Sector Perform rating following results.
Stanicky notes consumer margins are under pressure and they stay cautious into the May update.
... MorePerrigo (PRGO) Receives Leave To Judicially Review Irish Revenue Tax Assessment
February 25, 2019 8:39 AM ESTllPerrigo Company plc (NYSE: PRGO), a leading global provider of "Quality, Affordable, Self-Care Products", today announced that its subsidiary, Perrigo Pharma International DAC ("Elan Pharma"), has been granted leave by the Irish High Court to judicially review the November 29, 2018 issuance of a Notice of Amended Assessment by the Irish Office of the Revenue Commissioners for the calendar year ended December 31, 2013.
As... More
